|
HUE039908T2
(hu)
*
|
2009-02-02 |
2019-02-28 |
Glaxosmithkline Biologicals Sa |
Majom adenovírusból származó nukleinsav- és aminosav-szekvenciák, azt tartalmazó vektorok és alkalmazásuk
|
|
WO2011057248A2
(en)
|
2009-11-09 |
2011-05-12 |
Genvec, Inc. |
Simian adenovirus and methods of use
|
|
WO2011130627A2
(en)
|
2010-04-16 |
2011-10-20 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Chimpanzee adenoviral vector-based filovirus vaccines
|
|
EP2643465B1
(en)
*
|
2010-11-23 |
2016-05-11 |
The Trustees Of The University Of Pennsylvania |
Subfamily e simian adenovirus a1321 and uses thereof
|
|
WO2012089231A1
(en)
|
2010-12-30 |
2012-07-05 |
Okairòs Ag |
Paramyxovirus vaccines
|
|
TWI575070B
(zh)
|
2011-07-12 |
2017-03-21 |
傳斯堅公司 |
Ｈｂｖ聚合酶突變體
|
|
WO2013045668A2
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
|
TW201318637A
(zh)
|
2011-09-29 |
2013-05-16 |
Transgene Sa |
免疫療法組成物及用於治療ｃ型肝炎病毒感染之療程（一）
|
|
CA2850627C
(en)
|
2011-10-05 |
2024-05-21 |
Genvec, Inc. |
Affenadenovirus (gorilla) or adenoviral vectors and methods of use
|
|
CA2851251C
(en)
|
2011-10-05 |
2023-09-12 |
Genvec, Inc. |
Simian (gorilla) adenovirus or adenoviral vectors and methods of use
|
|
BR112014008167B1
(pt)
|
2011-10-05 |
2022-05-24 |
Genvec Inc |
Adenovírus ou vetor adenoviral e composição os compreendendo
|
|
WO2013074501A1
(en)
|
2011-11-14 |
2013-05-23 |
Crucell Holland B.V. |
Heterologous prime-boost immunization using measles virus-based vaccines
|
|
KR102044051B1
(ko)
|
2012-03-12 |
2019-11-12 |
얀센 백신스 앤드 프리벤션 비.브이. |
터미널 말단이 변경된 재조합 아데노바이러스의 배치
|
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
PL2844282T3
(pl)
|
2012-05-04 |
2019-11-29 |
Pfizer |
Antygeny związane z gruczołem krokowym i schematy immunoterapii oparte na szczepionce
|
|
AU2013262626B2
(en)
*
|
2012-05-18 |
2018-11-29 |
The Trustees Of The University Of Pennsylvania |
Subfamily E simian adenoviruses A1302, A1320, A1331 and A1337 and uses thereof
|
|
EP2855511B1
(en)
|
2012-05-29 |
2019-07-24 |
GenVec, Inc. |
Herpes simplex virus vaccine
|
|
EP2869841B1
(en)
|
2012-07-05 |
2021-08-25 |
GlaxoSmithKline Biologicals SA |
Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
|
|
WO2014005643A1
(en)
*
|
2012-07-05 |
2014-01-09 |
Okairos Ag |
Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
|
|
CA2891349C
(en)
|
2012-11-16 |
2023-07-18 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant adenoviruses and use thereof
|
|
SG11201507393TA
(en)
|
2013-03-14 |
2015-10-29 |
Salk Inst For Biological Studi |
Oncolytic adenovirus compositions
|
|
WO2014139587A1
(en)
|
2013-03-15 |
2014-09-18 |
Okairòs Ag |
Improved poxviral vaccines
|
|
PT2988780T
(pt)
|
2013-04-25 |
2019-03-25 |
Janssen Vaccines & Prevention Bv |
Polipeptídeos f de pré-fusão do rsv solúveis estabilizados
|
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
|
EP3154576A1
(en)
|
2014-06-13 |
2017-04-19 |
GlaxoSmithKline Biologicals S.A. |
Immunogenic combinations
|
|
AU2015311852B2
(en)
|
2014-09-03 |
2018-12-13 |
Bavarian Nordic A/S |
Methods and compositions for inducing protective immunity against filovirus infection
|
|
KR20190062617A
(ko)
|
2014-09-03 |
2019-06-05 |
버베리안 노딕 에이/에스 |
면역 반응을 증대시키기 위한 방법 및 조성물
|
|
WO2017025782A1
(en)
|
2014-09-17 |
2017-02-16 |
Glaxosmithkline Biologicals Sa |
Improved poxviral vaccines
|
|
ES2899913T3
(es)
|
2014-09-24 |
2022-03-15 |
Salk Inst For Biological Studi |
Virus tumorales oncolíticos y métodos de uso
|
|
MA40765B1
(fr)
|
2014-09-26 |
2021-04-30 |
Beth Israel Deaconess Medical Ct Inc |
Méthodes et compositions d'induction d'une immunité protectrice contre l'infection par le virus de l'immunodéficience humaine
|
|
CA2975432A1
(en)
|
2015-02-13 |
2016-08-18 |
Transgene Sa |
Immunotherapeutic vaccine and antibody combination therapy
|
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
|
AU2016249798B2
(en)
|
2015-04-14 |
2022-05-26 |
Janssen Vaccines And Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
|
DK3294326T3
(da)
|
2015-05-15 |
2021-05-31 |
Curevac Ag |
Prime-boost-regimer indbefattende indgivelse af mindst én mrna-konstruktion
|
|
BE1024824B1
(fr)
*
|
2015-06-12 |
2018-07-13 |
Glaxosmithkline Biologicals Sa |
Polynucleotides et polypeptides d'adenovirus
|
|
GB201514772D0
(en)
*
|
2015-08-19 |
2015-09-30 |
Glaxosmithkline Biolog Sa |
Adenovirus polynucleotides and polypeptides
|
|
WO2016198621A1
(en)
*
|
2015-06-12 |
2016-12-15 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
|
AU2016289496B2
(en)
|
2015-07-07 |
2021-02-04 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble pre-fusion RSV F polypeptides
|
|
CN107847580B
(zh)
|
2015-07-07 |
2022-08-12 |
扬森疫苗与预防公司 |
针对rsv的疫苗
|
|
GB201513176D0
(en)
*
|
2015-07-27 |
2015-09-09 |
Glaxosmithkline Biolog Sa |
Novel methods for inducing an immune response
|
|
PL3390430T3
(pl)
|
2015-12-15 |
2020-03-31 |
Janssen Vaccines & Prevention B.V. |
Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania
|
|
CA2954892A1
(en)
|
2016-01-19 |
2017-07-19 |
Pfizer Inc. |
Immunogens derived from tumor-associated antigens or nucleic acid molecules encoding the immunogens
|
|
EP3390645B1
(en)
|
2016-02-23 |
2022-09-14 |
Salk Institute for Biological Studies |
Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
|
|
WO2017147265A1
(en)
|
2016-02-23 |
2017-08-31 |
Salk Institute For Biological Studies |
High throughput assay for measuring adenovirus replication kinetics
|
|
RS64059B1
(sr)
*
|
2016-03-31 |
2023-04-28 |
The European Molecular Biology Laboratory |
Protein adenoviralnog omotača izveden iz vehikuluma za isporuku
|
|
MX2018012094A
(es)
|
2016-04-05 |
2019-01-10 |
Janssen Vaccines & Prevention Bv |
Proteinas f de prefusion del virus respiratorio sincicial (vrs) solubles y estabilizadas.
|
|
AU2017248018A1
(en)
|
2016-04-05 |
2018-09-27 |
Janssen Vaccines & Prevention B.V. |
Vaccine against RSV
|
|
CA3023022A1
(en)
|
2016-05-04 |
2017-11-09 |
Transgene Sa |
Combination therapy with cpg tlr9 ligand
|
|
BR112018072865A2
(pt)
|
2016-05-12 |
2019-04-30 |
Janssen Vaccines & Prevention B.V. |
promotor bidirecional potente e equilibrado
|
|
SG11201810078PA
(en)
|
2016-05-30 |
2018-12-28 |
Janssen Vaccines & Prevention Bv |
Stabilized pre-fusion rsv f proteins
|
|
US11001858B2
(en)
|
2016-06-20 |
2021-05-11 |
Janssen Vaccines & Prevention B.V. |
Potent and balanced bidirectional promoter
|
|
GB2549809C
(en)
|
2016-06-23 |
2022-11-30 |
Univ Oxford Innovation Ltd |
Vector
|
|
US10925956B2
(en)
|
2016-07-15 |
2021-02-23 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against a marburg virus infection
|
|
EP3484505A1
(en)
|
2016-07-15 |
2019-05-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against a marburg virus infection
|
|
MX2019002178A
(es)
*
|
2016-08-23 |
2019-09-18 |
Glaxosmithkline Biologicals Sa |
Peptidos de fusion con antigenos enlazados a fragmentos cortos de cadena invariante (cd74).
|
|
WO2018060288A1
(en)
|
2016-09-29 |
2018-04-05 |
Glaxosmithkline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
WO2018069316A2
(en)
|
2016-10-10 |
2018-04-19 |
Transgene Sa |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
|
JP7118062B2
(ja)
|
2016-12-09 |
2022-08-15 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
リサウイルス抗原を有するチンパンジーアデノウイルス構築物
|
|
AU2017375633C1
(en)
|
2016-12-12 |
2023-04-27 |
Salk Institute For Biological Studies |
Tumor-targeting synthetic adenoviruses and uses thereof
|
|
GB201701239D0
(en)
*
|
2017-01-25 |
2017-03-08 |
Glaxosmithkline Biologicals Sa |
Novel formulation
|
|
JP6721797B2
(ja)
|
2017-02-09 |
2020-07-15 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
異種遺伝子発現のための強力で短いプロモーター
|
|
WO2018185732A1
(en)
|
2017-04-06 |
2018-10-11 |
Janssen Vaccines & Prevention B.V. |
Mva-bn and ad26.zebov or ad26.filo prime-boost regimen
|
|
KR102945203B1
(ko)
|
2017-05-08 |
2026-03-31 |
시애틀 프로젝트 코포레이션 |
알파바이러스 신생항원 벡터
|
|
CA3062614A1
(en)
*
|
2017-05-10 |
2018-11-15 |
University Of Utah Research Foundation |
Compositions and methods of use of arc capsids
|
|
CA3061278A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
|
WO2018210871A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
|
BR112019026126A2
(pt)
|
2017-06-15 |
2020-06-30 |
Janssen Vaccines & Prevention B.V. |
vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
|
|
KR102582561B1
(ko)
*
|
2017-07-05 |
2023-09-26 |
노우스콤 아게 |
비인간 대형 유인원 아데노바이러스 핵산-서열 및 아미노산-서열, 이를 포함하는 벡터 및 그의 용도
|
|
RU2020100072A
(ru)
|
2017-07-11 |
2021-08-11 |
Пфайзер Инк. |
Иммуногенные композиции, содержащие cea, muc1 и tert
|
|
US20200230220A1
(en)
|
2017-07-12 |
2020-07-23 |
Nouscom Ag |
Neoantigen vaccine composition for treatment of cancer
|
|
EP3655539A1
(en)
|
2017-07-21 |
2020-05-27 |
GlaxoSmithKline Biologicals S.A. |
Chikungunya virus antigen constructs
|
|
WO2019023566A1
(en)
|
2017-07-28 |
2019-01-31 |
Janssen Vaccines & Prevention B.V. |
METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP
|
|
AU2018333566A1
(en)
|
2017-09-15 |
2020-02-27 |
Janssen Vaccines & Prevention B.V. |
Method for the safe induction of immunity against RSV
|
|
MX394509B
(es)
|
2017-10-16 |
2025-03-12 |
Glaxosmithkline Biologicals Sa |
Promotor mejorado
|
|
US11859199B2
(en)
|
2017-10-16 |
2024-01-02 |
Glaxosmithkline Biologicals Sa |
Adenoviral vectors with two expression cassettes encoding RSV antigenic proteins or fragments thereof
|
|
SG11202003058UA
(en)
|
2017-10-16 |
2020-04-29 |
Glaxosmithkline Biologicals Sa |
Replication competent adenoviral vectors
|
|
US20200299651A1
(en)
|
2017-10-16 |
2020-09-24 |
Glaxosmithkline Biologicals Sa |
Simian adenoviral vectors with two expression cassettes
|
|
WO2019086450A1
(en)
*
|
2017-10-31 |
2019-05-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
|
SG11202003399TA
(en)
|
2017-10-31 |
2020-05-28 |
Janssen Vaccines & Prevention Bv |
Adenovirus and uses thereof
|
|
MX421606B
(es)
|
2017-10-31 |
2025-03-14 |
Janssen Vaccines & Prevention Bv |
Vectores adenovirales y usos de estos
|
|
MX2020004488A
(es)
|
2017-10-31 |
2020-08-13 |
Janssen Vaccines & Prevention Bv |
Adenovirus y usos de estos.
|
|
CN111670046B
(zh)
|
2017-11-03 |
2024-11-08 |
Nouscom股份公司 |
疫苗的t细胞增强剂
|
|
WO2019099970A1
(en)
|
2017-11-20 |
2019-05-23 |
Janssen Pharmaceuticals Inc. |
Method of providing safe administration of adenoviral vectors encoding a zika virus antigen
|
|
WO2019118480A1
(en)
*
|
2017-12-11 |
2019-06-20 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant adenoviruses and uses thereof
|
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
|
JP2021506300A
(ja)
|
2017-12-19 |
2021-02-22 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
Ｂ型肝炎ウイルス（ｈｂｖ）に対する免疫応答を誘導するための方法および組成物
|
|
KR20200101394A
(ko)
|
2017-12-20 |
2020-08-27 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
엡스타인-바 바이러스 항원 구축물
|
|
BR112020019942A2
(pt)
|
2018-04-09 |
2021-01-26 |
Salk Institute For Biological Studies |
composições de adenovírus oncolítico com propriedades de replicação aprimoradas
|
|
MX2020013553A
(es)
|
2018-06-12 |
2021-02-26 |
Glaxosmithkline Biologicals Sa |
Polinucleotidos y polipeptidos de adenovirus.
|
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
|
EP3587581A1
(en)
|
2018-06-26 |
2020-01-01 |
GlaxoSmithKline Biologicals S.A. |
Formulations for simian adenoviral vectors having enhanced storage stability
|
|
EP3810277A1
(en)
|
2018-07-20 |
2021-04-28 |
Janssen Vaccines & Prevention B.V. |
Recombinant adenoviral vector expressing zika antigen with improved productivity
|
|
GB201812647D0
(en)
*
|
2018-08-03 |
2018-09-19 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Viral vectors and methods for the prevention or treatment of cancer
|
|
US12576143B2
(en)
*
|
2018-10-19 |
2026-03-17 |
Nouscom Ag |
Teleost invariant chain cancer vaccine
|
|
PE20211469A1
(es)
|
2018-11-13 |
2021-08-05 |
Janssen Vaccines And Prevention B V |
Proteinas f de prefusion del vrs estabilizadas
|
|
CN113424264B
(zh)
|
2018-11-15 |
2024-04-12 |
Nouscom股份公司 |
用于生成个性化癌症疫苗的癌症突变选择
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
BR112021017584A2
(pt)
|
2019-03-05 |
2021-11-09 |
Glaxosmithkline Biologicals Sa |
Regime e composições de imunização contra hepatite b
|
|
JP7406263B2
(ja)
*
|
2019-03-20 |
2023-12-27 |
国立大学法人北海道大学 |
改変アデノウイルス及びこれを含む医薬
|
|
SG11202113187WA
(en)
|
2019-05-30 |
2021-12-30 |
Gritstone Bio Inc |
Modified adenoviruses
|
|
CA3156471A1
(en)
*
|
2019-10-03 |
2021-04-08 |
Janssen Vaccines & Prevention B.V. |
Adenovirus vectors and uses thereof
|
|
EP4125973A4
(en)
*
|
2019-11-04 |
2024-03-13 |
Gritstone bio, Inc. |
NEOANTIGEN VACCINE THERAPY
|
|
EP4061405A1
(en)
|
2019-11-18 |
2022-09-28 |
Janssen Biotech, Inc. |
Vaccines based on mutant calr and jak2 and their uses
|
|
CN113088530A
(zh)
*
|
2020-01-08 |
2021-07-09 |
怡道生物科技(苏州)有限公司 |
一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
|
|
TW202204380A
(zh)
|
2020-01-31 |
2022-02-01 |
美商詹森藥物公司 |
用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗
|
|
WO2021156489A1
(en)
*
|
2020-02-05 |
2021-08-12 |
Imophoron Limited |
Engineered polypeptides derived from variable domain of adenovirus penton base
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
WO2021209897A1
(en)
|
2020-04-13 |
2021-10-21 |
Janssen Biotech, Inc. |
Psma and steap1 vaccines and their uses
|
|
KR20230009445A
(ko)
|
2020-05-11 |
2023-01-17 |
얀센 파마슈티칼즈, 인코포레이티드 |
안정화된 코로나바이러스 스파이크 단백질 융합 단백질
|
|
EP4171627A1
(en)
|
2020-06-29 |
2023-05-03 |
Janssen Vaccines & Prevention B.V. |
Vaccine combination against respiratory syncytial virus infection
|
|
EP4175664A2
(en)
|
2020-07-06 |
2023-05-10 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
WO2022009049A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
WO2022009051A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
A method for determining responsiveness to prostate cancer treatment
|
|
BR112022026974A2
(pt)
|
2020-07-06 |
2023-01-24 |
Janssen Pharmaceuticals Inc |
Proteínas de fusão estabilizadas de proteínas de pico de coronavírus
|
|
WO2022007774A1
(zh)
*
|
2020-07-06 |
2022-01-13 |
嘉兴安宇生物科技有限公司 |
一种新型黑猩猩腺病毒载体及其构建方法和应用
|
|
IL299571A
(en)
|
2020-07-08 |
2023-02-01 |
Janssen Sciences Ireland Unlimited Co |
Rna replicon vaccines against hbv
|
|
KR20230038496A
(ko)
|
2020-07-13 |
2023-03-20 |
트랜스진 |
면역 억제의 치료
|
|
IL300026A
(en)
*
|
2020-08-06 |
2023-03-01 |
Gritstone Bio Inc |
Multiepitope vaccine cassettes
|
|
WO2022140759A2
(en)
|
2020-12-23 |
2022-06-30 |
Janssen Biotech, Inc. |
Neoantigen peptide mimics
|
|
US20240228548A9
(en)
|
2021-02-19 |
2024-07-11 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion rsv fb antigens
|
|
WO2022175479A1
(en)
|
2021-02-19 |
2022-08-25 |
Janssen Vaccines & Prevention B.V. |
Vaccine combinations against respiratory syncytial virus strain a and b infections
|
|
AU2022249741A1
(en)
|
2021-04-01 |
2023-09-21 |
Msd International Business Gmbh |
Stabilized pre-fusion piv3 f proteins
|
|
JP2024512808A
(ja)
|
2021-04-05 |
2024-03-19 |
ヤンセン バイオテツク，インコーポレーテツド |
Ｃａｌｒ及びｊａｋ２ｔ細胞受容体
|
|
WO2022218997A1
(en)
|
2021-04-12 |
2022-10-20 |
Centre National De La Recherche Scientifique (Cnrs) |
Novel universal vaccine presenting system
|
|
CN117915940A
(zh)
|
2021-06-21 |
2024-04-19 |
Nouscom股份公司 |
包含经编码的佐剂的疫苗组合物
|
|
WO2023020939A1
(en)
|
2021-08-17 |
2023-02-23 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023026182A1
(en)
|
2021-08-24 |
2023-03-02 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023047349A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized coronavirus spike protein fusion proteins
|
|
WO2023047348A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized corona virus spike protein fusion proteins
|
|
WO2023111725A1
(en)
|
2021-12-14 |
2023-06-22 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
EP4448802A1
(en)
|
2021-12-16 |
2024-10-23 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion hmpv fusion proteins
|
|
WO2023198815A1
(en)
|
2022-04-14 |
2023-10-19 |
Janssen Vaccines & Prevention B.V. |
Sequential administration of adenoviruses
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
WO2024061759A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Stabilized coronavirus s proteins
|
|
EP4590690A1
(en)
|
2022-09-23 |
2025-07-30 |
Janssen Vaccines & Prevention B.V. |
Pre-fusion human piv1 f proteins
|
|
WO2024074584A1
(en)
|
2022-10-06 |
2024-04-11 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion piv3 f proteins
|
|
WO2025158316A1
(en)
|
2024-01-26 |
2025-07-31 |
Janssen Biotech, Inc. |
Ovarian neoantigens and use thereof
|